Der var en lille forekomst af myopati (defineret som serumkreatininkinase- niveauer, der 10 gange overskred den øvre grænse for normalværdi), som kun forekom hos 11 simvastatin- behandlede patienter og 6 placebo - behandlede patienter.
There was a low incidence of myopathy (defined as serum creatine kinase levels exceeding 10 times the upper limit of normal), that occurred in only 11 simvastatin-treated patients and six placebo-treated patients.